Description du projet
L’IA permet à un dispositif d’USI non invasif de maintenir en temps réel des taux de glycémie sains
Le glucose est la principale source d’énergie pour tous les processus métaboliques de nos cellules. Le maintien d’un bon équilibre est essentiel à tout, des fonctions cérébrales à la cicatrisation des blessures, en passant par la contraction des muscles. Au cours des deux dernières décennies, il est devenu de plus en plus évident qu’une homéostasie inadéquate du glucose chez les patients en unité de soins intensifs (USI) est associée à une morbidité et une mortalité importantes. La surveillance continue du glucose peut détecter plus efficacement l’hyperglycémie et l’hypoglycémie avant que la situation ne se détériore, par rapport aux tests sporadiques et aux analyses hors ligne. Le projet ContiTRACE, financé par l’UE, jette les bases de la commercialisation de son dispositif non invasif de surveillance continue du glucose et de perfusion automatique d’insuline. Le dispositif ContiTRACE promet de réduire considérablement la charge de travail des soignants et les coûts du système de soins de santé tout en améliorant les résultats des patients en USI.
Objectif
Intensive Care Units (ICUs) require careful monitoring of blood glucose levels and insulin infusion to keep patients within safe physiological levels. Fluctuations of blood glucose are directly related to an increased risk of death and comorbidities. However, blood glucose monitoring (BGM) is still made by intermittent and manual offline analysis of blood samples. This technique proves inefficient (need 17% caregivers time), costly (€300 per patient) and increments mortality in hospital ICUs by 40% due to irregular glucose level adjustments upon measurements. After 15+ years of experience in developing glucose monitoring sensors, we at TRACE are taking on our next big step to penetrate the medical device sector with ContiTRACE: an AI powered automated non-invasive medical device for continuous BGM. Our patented ContiTRACE is able to measure glycaemic levels every 2 minutes (automatically) and automatically infuse insulin when needed. It is also capable of self-calibrating and has standardized body accesses, enhancing safety and minimising discomfort for the ICU patient. This will allow 1) caregivers to decrease their workload, 2) doctors to take informed decisions and 3) the healthcare system to optimize their limited human, economic and material resources by providing savings of more than 50% of BGM related cost. Our business model is twofold. We will sell the medical device (5 years lifecycle), and the consumables (max. 4 days duration per set) to private and public hospital ICUs. Our draft forecast (2022-2026) estimates profits of 14.4 M€ with a Return on Investment of 10.7 by the 5th commercial year allowing us to increase x10 our company headcounts in five commercial years. Although newcomers to the medical sector we have the support of key players among regulatory companies (Profil), manufacturers (Sasse Elektronik), pharma companies (Sanofi-Aventis, Pfizer and Roche) and distributors (Care Diagnostica) to take on the BGM challenge.
Champ scientifique
- social sciencessociologydemographymortality
- medical and health sciencesclinical medicinecritical care medicine
- social scienceseconomics and businessbusiness and managementbusiness models
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensors
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
38106 BRAUNSCHWEIG
Allemagne
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.